⌘K
Loading ticker…
As of 2026-08-24, Processa Pharmaceuticals, Inc. Common (PCSA) has a 3-month relative strength percentile of 22 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 10.6%, relative volume 0.05×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PCSA is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.2% / -33.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PCSA appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $32K notional.
Held by 1 ETFs · $32K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $32K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PCSA Jan avg: -27.32% median: -24.36% win: 25% σ: 28.39% n: 4 2022-04-12 → 2026-07-31 | PCSA Feb avg: -15.15% median: -18.59% win: 25% σ: 13.84% n: 4 2022-04-12 → 2026-07-31 | PCSA Mar avg: -11.36% median: -14.60% win: 25% σ: 22.15% n: 4 2022-04-12 → 2026-07-31 | PCSA Apr avg: -3.46% median: -7.82% win: 40% σ: 21.15% n: 5 2022-04-12 → 2026-07-31 | PCSA May avg: -6.67% median: -5.18% win: 20% σ: 16.45% n: 5 2022-04-12 → 2026-07-31 | PCSA Jun avg: -2.63% median: -19.76% win: 40% σ: 33.97% n: 5 2022-04-12 → 2026-07-31 | PCSA Jul avg: 1.40% median: 2.49% win: 60% σ: 10.24% n: 5 2022-04-12 → 2026-07-31 | PCSA Aug avg: -21.06% median: -19.96% win: 0% σ: 12.24% n: 4 2022-04-12 → 2026-07-31 (current) | PCSA Sep avg: -9.33% median: -9.27% win: 25% σ: 11.33% n: 4 2022-04-12 → 2026-07-31 | PCSA Oct avg: 30.28% median: 17.05% win: 50% σ: 54.13% n: 4 2022-04-12 → 2026-07-31 | PCSA Nov avg: 9.64% median: -5.17% win: 50% σ: 50.44% n: 4 2022-04-12 → 2026-07-31 | PCSA Dec avg: -42.21% median: -44.90% win: 0% σ: 13.62% n: 4 2022-04-12 → 2026-07-31 |